Literature DB >> 12383042

The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin.

Richard A Faaij1, Jacobus Burggraaf, Rik C Schoemaker, Rik de Greef, Adam F Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12383042     DOI： 10.2165/00003088-200241002-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  10 in total

1.  The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers.

Authors:  R A Faaij; J M van Griensven; R C Schoemaker; T Goggin; A Guenzi; J M Kroon; J Burggraaf; A F Cohen
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

2.  Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.

Authors:  Carolyne Lieu; Juan Shi; François Donat; Robert Van Horn; William Brian; John Newton; Leon Delbressine; Ria Vos
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins.

Authors:  Francis Paolucci; Marie-Christine Claviés; François Donat; José Necciari
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin.

Authors:  S Toon; B L Holt; F G Mullins; R Bullingham; L Aarons; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

5.  Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity.

Authors:  L V Rao; O Nordfang; A D Hoang; U R Pendurthi
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

6.  Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.

Authors:  P M Hobbelen; T G van Dinther; G M Vogel; C A van Boeckel; H C Moelker; D G Meuleman
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

7.  Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.

Authors:  S Toon; K J Hopkins; F M Garstang; L Aarons; A Sedman; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

8.  Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.

Authors:  S Toon; K J Hopkins; F M Garstang; M Rowland
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Changes in plasma warfarin levels and variations in steady-state prothrombin times.

Authors:  R H White; H Zhou; P Romano; D Mungall
Journal:  Clin Pharmacol Ther       Date:  1995-11       Impact factor: 6.875

10.  Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.

Authors:  D Carrie; C Caranobe; S Saivin; G Houin; M Petitou; J C Lormeau; C Van Boeckel; D Meuleman; B Boneu
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113
  10 in total
  3 in total

1.  Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.

Authors:  Carolyne Lieu; Juan Shi; François Donat; Robert Van Horn; William Brian; John Newton; Leon Delbressine; Ria Vos
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  The pharmacokinetics of fondaparinux sodium in healthy volunteers.

Authors:  François Donat; Jean Pierre Duret; Alix Santoni; Roger Cariou; José Necciari; Harry Magnani; Rik de Greef
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Clinical pharmacology of direct and indirect factor Xa inhibitors.

Authors:  Hans-Juergen Rupprecht; Ralf Blank
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.